Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2020 08:00 ET | Source: Immuron Limited

Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020

MELBOURNE, Australia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
November 21, 2019 07:00 ET | Source: Immuron Limited

Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea

Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to prevent TD planned for...
November 04, 2019 11:30 ET | Source: Immuron Limited

Immuron Receives AUD $0.53M R&D Tax Concession Refund

MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
October 14, 2019 07:30 ET | Source: Immuron Limited

Immuron North American Q1 Sales Up 111% YoY

Key Highlights: First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUDQ1 US Travelan® sales increased by +81% YoY to $232K AUDGlobal Immuron sales continued an upward...
October 02, 2019 09:00 ET | Source: Immuron Limited

New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

Key Highlights: AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic targeting Campylobacter and ETECNaval Medical...
September 04, 2019 06:00 ET | Source: Immuron Limited

U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea

Key Highlights: Major goal of study was to evaluate Travelan®’s ability to bind and react to a variety of infectious Vibrio cholera strains from Southeast Asia Pathogenic bacteria evaluated in study...
August 16, 2019 06:00 ET | Source: Immuron Limited

Immuron to Commence Non-Deal Investor Roadshow

MELBOURNE, Australia, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
August 08, 2019 12:00 ET | Source: Immuron Limited

Immuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial

MELBOURNE, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
July 17, 2019 06:00 ET | Source: Immuron Limited

Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments

MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an investor...
July 17, 2019 06:00 ET | Source: Immuron Limited

Immuron Prices Underwritten Public Offering of ADSs

MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...